Insiders have been trading these 5 stocks: ((ELF)), ((CCI)), ((DASH)), ((STAG)) and ((TNYA)). Here is a breakdown of their recent trades and their value.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Director Matthew Farrell just put real money behind his conviction in e.l.f. Beauty, scooping up 5,000 shares in a single insider purchase. The buy, worth $464,800, signals notable confidence in the company’s future trajectory and will catch the eye of investors tracking executive skin-in-the-game moves.
At Crown Castle, the tone is very different as key executives are heading for the exit, at least with some shares. EVP & GC Edward B JR Adams unloaded 4,650 shares for $401,481, while VP & Controller Robert Sean Collins sold 3,000 shares worth $262,470, moves that may prompt questions about near-term expectations.
DoorDash is seeing a wave of insider selling that stands out for both size and breadth of participation. From CAO Gordon Lee’s 2,693 shares at $472,594 to President & COO Prabir Adarkar’s 15,692 shares at $2,753,789 and CFO Ravi Inukonda’s 15,443 shares at $2,710,092, insiders including directors Stanley Tang and Andy Fang collectively moved millions, capped by CBO Keith Yandell and GC & Secretary Tia Sherringham selling $864,814 and $1,464,639 of stock.
Stag Industrial is also in the spotlight as multiple top leaders trimmed their stakes in sizable chunks. Director Virgis Colbert sold 18,000 shares for $685,399, CEO & President William Crooker exited 93,732 shares for $3,671,482, and EVP, CFO & Treas Pinard Matts sold 25,242 shares worth $988,729, a cluster of sales that could influence sentiment around the REIT.
Tenaya Therapeutics saw its largest moves from a single powerful player, as significant shareholder COLUMN GROUP III GP, LP dramatically cut back its position. The firm sold 4,170,266 shares for $2,368,270 and then followed up with another 829,734 shares for $500,017, signaling an aggressive step-down in exposure that biotech investors will scrutinize closely.

